Clinical audit for the adherence to safety monitoring for pioglitazone use in patients with type 2 diabetes in the Al-Wazarat primary care center, Saudi Arabia

php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Clinical Audit 2017:9 25–31 Clinical Audit Dovepress

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  2017-07-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/CA.S122952
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Global estimates of diabetes prevalence for 2013 and projections for 2035.

  2014cited by this paper
• Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings

  2014cited by this paper
• Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013

  2013cited by this paper
• Drug utilization, safety and clinical use of Actos and Avandia

  2013cited by this paper
• Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies

  2013cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

  2012cited by this paper
• Oral Antidiabetic Agents

  2012cited by this paper
• Pioglitazone in Clinical Practice: Where Are We Now?

  2012cited by this paper
• Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.

  2012cited by this paper
• Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review

  2010cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2009cited by this paper
• Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.

  2006cited by this paper
• Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.

  2005cited by this paper
• Diabetes mellitus in Saudi Arabia.

  2004cited by this paper
• Postmarketing Surveillance Study of the Efficacy and Tolerability of Pioglitazone in Insulin-Resistant Patients with Type 2 Diabetes Mellitus in General Practice

  2003cited by this paper
• Pioglitazone: mechanism of action.

  2001cited by this paper
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

  2000cited by this paper

• Maturity of Clinical Audit Concept in Saudi Arabian Health Care Practice: A Review

  2022cites this paper